Capricor Therapeutics Updates on Duchenne Treatment Progress
Buy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical Advancements
HC Wainwright & Co. : The Capricorn Therapeutics (CAPR.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $40.00.
HC Wainwright & Co. : The Capricorn Therapeutics (CAPR.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $40.00.
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics with a Buy and maintains $40 price target.
Capricor Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 663.36% HC Wainwright & Co. → $40 Reiterates Buy → Buy 03/01/2024 663.36% HC Wainwright & Co. →
Optimistic Outlook for Capricor Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strong Financial Position
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug
Capricor Therapeutics (CAPR) said Wednesday the US Food and Drug Administration granted another Type-B meeting in Q2 to move ahead with the biologics license application for CAP-1002 for treating Duch
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals Among Healthcare Movers
Capricor Therapeutics Announces Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy, FDA Feedback Supports Requests For Pre-BLA Meeting And Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting
Capricor Therapeutics Announces Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy, FDA Feedback Supports Requests For Pre-BLA Meeting And Subsequent Rolling BLA Submission F
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Stock Catapults 51% Though Its Price And Business Still Lag The Industry
Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares have had a really impressive month, gaining 51% after a shaky period beforehand. Looking back a bit further, it's encouraging to see the stock is up
Solid Biosciences Gets FDA Rare Pediatric Disease Status for DMD Therapy
Canopy Growth, Capricor Therapeutics, GT Biopharma Among Healthcare Movers
This Just In: Analysts Are Boosting Their Capricor Therapeutics, Inc. (NASDAQ:CAPR) Outlook for This Year
Shareholders in Capricor Therapeutics, Inc. (NASDAQ:CAPR) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts greatly increased
Catalyst Announces US Launch of Duchenne MD Drug Agamree
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
Capricor Therapeutics, Inc. Is Worried About This – Should You Be Worried Too?
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare
Capricor Therapeutics: Strong Buy Rating Backed by Robust Financials and Promising Clinical Progress
No Data